GLP-2 Therapy for Short Bowel Syndrome
Introduction to GLP-2 Therapy
- The native GLP-2 peptide has an extremely short half-life and would be rapidly degraded in the gastrointestinal tract if taken orally, making oral administration pharmacologically impossible 1, 2
Patient Selection and Pre-Treatment Requirements
- The American Gastroenterological Association recommends that adults undergo colonoscopy and upper GI endoscopy with removal of any polyps found before starting teduglutide therapy 3, 4
- The American Gastroenterological Association recommends that teduglutide should only be used after optimizing dietary management and conventional SBS treatments have failed to achieve enteral independence 3, 4, 6, 7
Clinical Efficacy
- Teduglutide increases wet weight absorption by approximately 750 g/day, which is clinically meaningful for reducing parenteral fluid requirements 1, 2, 9
- Teduglutide increases villus height by 38-45% and crypt depth by 18-22% in jejunostomy patients 1, 2, 9
Critical Safety Concerns
- The American Gastroenterological Association warns that teduglutide enhances growth of colonic polyps and can accelerate gastrointestinal cancer progression 3, 4, 6
Prescriber Requirements
- The American Gastroenterological Association recommends that teduglutide should only be prescribed by physicians experienced in diagnosing and managing SBS who have the facilities to objectively evaluate benefits versus risks 3, 4, 7